» Articles » PMID: 32864253

Temporal Trends of Intracranial Hemorrhage Among Immune Thrombocytopenia Hospitalizations in the United States

Overview
Journal Cureus
Date 2020 Sep 1
PMID 32864253
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background:  Intracranial hemorrhage (ICH) is a rare but severe complication in patients with immune thrombocytopenia (ITP). We aimed to examine the incidence and outcomes of ICH among ITP hospitalizations and factors associated with it. Additionally, we studied resource utilization for these hospitalizations.

Methods:  Using National (Nationwide) Inpatient Sample, International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification (ICD-9-CM/ICD-10-CM) codes, we studied ITP hospitalizations with occurrence of ICH between 2007 and 2016.

Result:  Out of 348,906 weighted ITP hospitalizations, ICH occurred in 3,408 encounters (incidence 1.1 ± 0.04%). The incidence remained stable over time (2007-2008: 1.01%, 2015-2016: 1.20%; P = 0.3). People with age ≥25 years, especially those aged ≥65 years (odds ratio [OR] 3.69, 95% confidence interval [CI] 2.34-5.84), or those with gastrointestinal bleed (OR 1.60, 95% CI 1.18-2.16) were significantly more likely to develop ICH. Female gender (OR 0.81, 95% CI 0.68-0.97) had lower odds for developing ICH. Overall mortality in ITP hospitalizations with ICH was 26.7%. Length of stay (LOS) was longer (4.8 vs. 2.6 days) and costs of hospitalization (COH) were higher ($20,081 vs. $8,355) in ICH hospitalizations compared to non-ICH ITP hospitalizations. Increasing age and comorbidities such as gastrointestinal bleed, hematuria, and other bleeding were also associated with longer LOS and higher COH.

Conclusion: Although rare, ICH in ITP was associated with a high mortality and increased resource utilization. Clinicians should be cognizant of factors associated with risk of ICH in ITP, and future studies should reassess the ICH trends to study the impact of novel therapeutic options such as thrombopoietin receptor agonists.

Citing Articles

Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review.

Chowdhury S, Sirotich E, Guyatt G, Gill D, Modi D, Venier L Eur J Haematol. 2024; 114(3):458-468.

PMID: 39552264 PMC: 11798764. DOI: 10.1111/ejh.14351.


Treatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis.

Sirotich E, Nazaryan H, Chowdhury S, Guyatt G, Agarwal A, Leong R Syst Rev. 2024; 13(1):21.

PMID: 38184622 PMC: 10770981. DOI: 10.1186/s13643-023-02436-6.


Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality.

Hallan D, Simion C, Sciscent B, Lee J, Rizk E Cureus. 2022; 14(4):e24447.

PMID: 35637831 PMC: 9128758. DOI: 10.7759/cureus.24447.

References
1.
Neunert C, Noroozi N, Norman G, Buchanan G, Goy J, Nazi I . Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2014; 13(3):457-64. PMC: 4991942. DOI: 10.1111/jth.12813. View

2.
Danese M, Lindquist K, Gleeson M, Deuson R, Mikhael J . Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009; 84(10):631-5. DOI: 10.1002/ajh.21500. View

3.
Melboucy-Belkhir S, Khellaf M, Augier A, Boubaya M, Levy V, Le Guenno G . Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. Am J Hematol. 2016; 91(12):E499-E501. DOI: 10.1002/ajh.24529. View

4.
Tarantino M, Danese M, Klaassen R, Duryea J, Eisen M, Bussel J . Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. Platelets. 2016; 27(5):472-8. PMC: 4926780. DOI: 10.3109/09537104.2016.1143923. View

5.
Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T . High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991; 77(1):31-3. View